Frequency of and variables associated with the EGFR mutation and its subtypes

No abstract is available for this paper.

• Publication year

  2010

• Venue

  International Journal of Cancer

• Publication date

  2010-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1002/ijc.24746PMID 19609951
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy.

  2009cited by this paper
• Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

  2008cited by this paper
• Peptide nucleic acid–locked nucleic acid polymerase chain reaction clamp‐based detection test for gefitinib‐refractory T790M epidermal growth factor receptor mutation

  2008cited by this paper
• Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous chemotherapy.

  2007cited by this paper
• Reliability of the peptide nucleic acid‐locked nucleic acid polymerase chain reaction clamp‐based test for epidermal growth factor receptor mutations integrated into the clinical practice for non‐small cell lung cancers

  2007cited by this paper
• Prospective Validation for Prediction of Gefitinib Sensitivity by Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer

  2007cited by this paper
• Biological and clinical implications of EGFR mutations in lung cancer

  2006cited by this paper
• Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations.

  2006cited by this paper
• Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

  2006cited by this paper
• A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations

  2006cited by this paper
• Mutations in the epidermal growth factor receptor gene are linked to smoking-independent, lung adenocarcinoma

  2005cited by this paper
• The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers.

  2005cited by this paper
• Genetic heterogeneity of the epidermal growth factor receptor in non-small cell lung cancer cell lines revealed by a rapid and sensitive detection system, the peptide nucleic acid-locked nucleic acid PCR clamp.

  2005cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• A high-resolution recombination map of the human genome

  2002cited by this paper

• Prognostic factors of epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitor (TKI): a nationwide registry study in China

  2026cites this paper
• Clinical impact of continuing osimertinib beyond progression versus best supportive care in EGFR-mutated advanced non-small cell lung cancer: a multi-institutional retrospective study

  2025cites this paper
• Epidermal Growth Factor Mutation Analysis in Patients With Bronchogenic Adenocarcinoma: Prevalence and Clinical Profile-Outlook From a Tertiary Care Center in India

  2025cites this paper
• Impact of cigarette smoking and gender on EGFR mutation status in Iraqi lung cancer patients

  2025cites this paper
• A Review of Genetic Alteration Correlated with Primary and Acquired Resistance to EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer

  2025cites this paper
• A retrospective, descriptive analysis identifying non‑small cell lung cancer molecular markers

  2024cites this paper
• Digital Profiling of Tumor Extracellular Vesicle-associated RNAs Directly from Unprocessed Blood Plasma

  2024cites this paper
• Common epidermal growth factor receptor mutations in north Indian patients with non-small cell lung carcinoma: evidence from real-time polymerase chain reaction.

  2024cites this paper
• Immunohistochemical analysis of epidermal growth factor receptor as a predictive biomarker in lung adenocarcinoma – A cross-sectional study of 33 cases on computed tomography-guided core needle biopsy specimens

  2024cites this paper
• Dermatologic toxicities in epidermal growth factor receptor: a comprehensive pharmacovigilance study from 2013 to 2023

  2024cites this paper
• Effect of primary tumor volume on survival of concurrent chemoradiotherapy in stage IV non‐small cell lung cancer

  2024cites this paper
• The Epidermal Growth Factor, Anaplastic Lymphoma Kinase, and ROS Proto-oncogene 1 Mutation Profile of Non-Small Cell Lung Carcinomas in the Turkish Population: A Single-Center Analysis

  2024cites this paper
• Evaluation of the clinical significance of long non-coding RNA MALAT1 genetic variants in human lung adenocarcinoma

  2024cites this paper
• Detection of EGFR gene polymorphisms in non-small cell lung cancer Egyptian patients: a case–control study

  2023cites this paper
• Frequency of Epidermal Growth Factor Receptor Mutations among Iraqi Non-small Cell Lung Cancer Patients

  2022cites this paper
• Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors

  2022cites this paper
• Association of smoking status with non-small cell lung cancer patients harboring uncommon epidermal growth factor receptor mutation

  2022cites this paper
• Mutational Analysis of EGFR Mutations in Non-Small Cell Lung Carcinoma—An Indian Perspective of 212 Patients

  2022cites this paper
• Correlation of Epidermal Growth Factor Receptor Mutation With Major Histologic Subtype of Lung Adenocarcinoma According to IASLC/ATS/ERS Classification

  2022cites this paper
• Non-Small Cell Lung Cancer with Malignant Pleural Effusion May Require Primary Tumor Radiotherapy in Addition to Drug Treatment

  2022cites this paper
• Synergistic Antitumor Effect of Taxanes and CDK4/6 Inhibitor in Lung Cancer Cells and Mice Harboring KRAS Mutations

  2021cites this paper
• Sex dimorphism in response to targeted therapy and immunotherapy in non-small cell lung cancer patients: a narrative review

  2021cites this paper
• 肺癌合并其他器官多原发癌的临床特点分析

  2021cites this paper
• Prognostic Model to Predict Overall Survival for Metastatic Non-Small Cell Lung Cancer Patients Treated With Chemotherapy Combined With Concurrent Radiation Therapy to the Primary Tumor: Analysis From Two Prospective Studies

  2021cites this paper
• Molecular approaches to lung cancer prevention.

  2021cites this paper
• Bioinformatics and integrated analyses of prognosis-associated key genes in lung adenocarcinoma

  2021cites this paper
• Efficacy of Icotinib, an EGFR Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer Patients with Exon 19 Deletion and Exon 21 L858R: A Retrospective Analysis in China

  2021cites this paper
• Distinct EGFR Mutation Pattern in Patients With Non-Small Cell Lung Cancer in Xuanwei Region of China: A Systematic Review and Meta-Analysis

  2020influential citation
• High expression of RRM2 as an independent predictive factor of poor prognosis in patients with lung adenocarcinoma

  2020cites this paper
• Frequency and types of EGFR mutations in Moroccan patients with non–small cell lung cancer

  2020cites this paper
• Cell-Free Circulating Tumour DNA Blood Testing to Detect EGFR T790M Mutation in People With Advanced Non-Small Cell Lung Cancer: A Health Technology Assessment.

  2020cites this paper
• Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations.

  2020cites this paper
• Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer

  2020cites this paper
• Human skin biomarkers relationship to response to treatment with tyrosine kinase inhibitors in advanced EGFR‐mutated lung adenocarcinoma

  2020cites this paper
• Adenocarcinoma pulmonar con rearreglo ALK: un fenotipo clínico y tomográfico distinto

  2020cites this paper
• Nomogram based on preoperative CT imaging predicts the EGFR mutation status in lung adenocarcinoma

  2020cites this paper
• Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations.

  2019cites this paper
• Brain surgery in combination with tyrosine kinase inhibitor and whole brain radiotherapy for epidermal growth factor receptor-mutant non-small-cell lung cancer with brain metastases

  2019cites this paper
• Analysis of Genetic Alterations in Tunisian Patients with Lung Adenocarcinoma

  2019cites this paper
• Simultaneous Detection of the T790M and L858R Mutations in the EGFR Gene by Oligoribonucleotide Interference-PCR

  2019cites this paper
• Association between EGFR mutation and ageing, history of pneumonia and gastroesophageal reflux disease among patients with advanced lung cancer.

  2019cites this paper
• Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice

  2019cites this paper
• Lung Cancer Biomarkers in Proximal Fluids

  2019cites this paper
• Clinicopathologic Characteristics of EGFR Mutations in Non-Small Cell Lung Cancer (NSCLC) in Central New York

  2018cites this paper
• Different subtypes of EGFR exon19 mutation can affect prognosis of patients with non-small cell lung adenocarcinoma

  2018cites this paper
• Epidemiological Characteristics, EGFR Status and Management Patterns of Advanced Non-small Cell Lung Cancer Patients: The Greek REASON Observational Registry Study

  2018cites this paper
• Leptomeningeal metastasis.

  2018cites this paper
• Development of the Japanese version of an information aid to provide accurate information on prognosis to patients with advanced non–small-cell lung cancer receiving chemotherapy: a pilot study

  2018cites this paper
• Distribution of molecular subtypes of advanced lung adenocarcinoma and clinical outcomes in a center of Argentina.

  2018cites this paper
• Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis

  2018cites this paper
• EGFR mutation status in Tunisian non-small-cell lung cancer patients evaluated by mutation-specific immunohistochemistry

  2018cites this paper
• Clinical efficacy evaluation of tyrosine kinase inhibitors for non-adenocarcinoma lung cancer patients harboring EGFR-sensitizing mutations

  2017cites this paper
• The Taxonomic and Functional Nature of Plant-Associated Microbiomes

  2017influential citation
• Patient-Derived Xenografts From Lung Cancer and Their Potential Applications

  2017cites this paper
• Methods in Molecular Diagnosis

  2017cites this paper
• Citrus Bioactives as Prospective Therapeutic Agents for the Modulation of Colon Cancer

  2017cites this paper
• Molecular epidemiological study of microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene using immunohistochemistry as a cost effective alternative to fluorescence in situ hybridization for Indian patients with adenocarcinoma lung

  2017cites this paper
• Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis

  2017cites this paper
• Clinicopathological features of Chinese lung cancer patients with epidermal growth factor receptor mutation.

  2017cites this paper
• Salinomycin acts through reducing AKT‐dependent thymidylate synthase expression to enhance erlotinib‐induced cytotoxicity in human lung cancer cells

  2017cites this paper
• Role of epidermal growth factor receptor in lung cancer and targeted therapies.

  2017cites this paper
• Prognostic value of rare and complex mutations in EGFR and serum levels of soluble EGFR and its ligands in non-small cell lung carcinoma patients.

  2017cites this paper
• High probability and frequency of EGFR mutations in non-small cell lung cancer with brain metastases

  2017cites this paper
• Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case report

  2017cites this paper
• Might radiation therapy in addition to chemotherapy improve overall survival of patients with non-oligometastatic Stage IV non-small cell lung cancer?: Secondary analysis of two prospective studies

  2016cites this paper
• An Analysis of EGFR Mutations among 1506 Cases of Non-Small Cell Lung Cancer Patients in Guangxi, China

  2016cites this paper
• Compound Library Screening Identified Cardiac Glycoside Digitoxin as an Effective Growth Inhibitor of Gefitinib-Resistant Non-Small Cell Lung Cancer via Downregulation of α-Tubulin and Inhibition of Microtubule Formation

  2016influential citation
• Which Epidemiological Factors Have the Most Influence on the EGFR Mutation Frequency in Lung Adenocarcinoma?

  2016cites this paper
• Molecular Targeted Therapies for the Treatment of Leptomeningeal Carcinomatosis: Current Evidence and Future Directions

  2016cites this paper
• Epidermal growth factor receptor gene mutation status of non-small cell lung cancer in Han and ethnic minorities in the Guangxi province of China

  2016influential citation
• Lung cancer mutation profile of EGFR, ALK, and KRAS: Meta-analysis and comparison of never and ever smokers.

  2016cites this paper
• Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography

  2016cites this paper
• The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis

  2016cites this paper
• Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.

  2016cites this paper
• Treatments and outcomes of advanced/recurrent non-small cell lung cancer harboring the EGFR T790M mutation: a retrospective observational study of 141 patients in Japan.

  2016cites this paper
• Activation of the BMP-BMPR pathway conferred resistance to EGFR-TKIs in lung squamous cell carcinoma patients with EGFR mutations

  2015cites this paper
• Clinical likelihood of sporadic primary EGFR T790M mutation in EGFR-mutant lung cancer.

  2015cites this paper
• L 858 R ‐ positive lung adenocarcinoma with KRAS G 12 V , EGFR T 790 M and EGFR L 858 R mutations : A case report

  2015cites this paper
• Gefitinib: a review of its use in adults with advanced non-small cell lung cancer

  2015cites this paper
• 4′-Geranyloxyferulic acid: an overview of its potentialities as an anti-cancer and anti-inflammatory agent

  2015cites this paper
• Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung

  2015cites this paper
• L858R-positive lung adenocarcinoma with KRAS G12V, EGFR T790M and EGFR L858R mutations: A case report.

  2015cites this paper
• The mutation rates of EGFR in non-small cell lung cancer and KRAS in colorectal cancer of Chinese patients as detected by pyrosequencing using a novel dispensation order

  2015cites this paper
• Predictive biomarkers in precision medicine and drug development against lung cancer

  2015cites this paper
• Inactivated Sendai Virus Strain Tianjin Induces Apoptosis in Breast Cancer MCF-7 Cells by Promoting Caspase Activation and Fas/FasL Expression

  2015cites this paper
• Reliable EGFR mutation testing in ultrasound-guided supraclavicular lymph node fine-needle aspirates: a cohort study with diagnostic performance analysis

  2015cites this paper
• Rociletinib—An Investigational Therapy in Patients with Previously Treated EGFR Mutant-positive Non-small Cell Lung Cancer

  2015cites this paper
• Analysis of an EGFR mutation by PNA clamping method in lung carcinoid tumors

  2015cites this paper
• Epidermal growth factor receptor mutations in Japanese men with lung adenocarcinomas.

  2015cites this paper
• Roles of immunohistochemical staining in diagnosing pulmonary squamous cell carcinoma.

  2015cites this paper
• Epidermal growth factor receptor in non-small cell lung cancer.

  2015influential citation
• Three-Dimensional Radiation Therapy to the Primary Tumor With Concurrent Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer: Results of a Multicenter Phase 2 Study From PPRA-RTOG, China.

  2015cites this paper
• Detection of EGFR-TK Domain–activating Mutations in NSCLC With Generic PCR-based Methods

  2015cites this paper
• Polimorfismos genéticos e carcinoma de pulmão de células não pequenas: os paradigmas do futuro

  2014cites this paper
• Anti-Inflammatory and Chemopreventive Potentials of Citrus Auraptene

  2014cites this paper
• Genetic polymorphisms and non-small-cell lung cancer: future paradigms

  2014cites this paper
• Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status.

  2014cites this paper
• Evaluation of gefitinib efficacy according to body surface area in patients with non-small cell lung cancer harboring an EGFR mutation

  2014cites this paper
• Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q

  2014cites this paper
• Additional prognostic role of EGFR activating mutations in lung adenocarcinoma patients with brain metastasis: integrating with lung specific GPA score.

  2014cites this paper